我国肝癌干细胞治疗研究取得重大突破

ag2017

2 P; V. G; V  H3 f: X" U& O
0 \/ y: p! ]; [. V2 P' R! ~- |自然科学基金会网站5月6日消息，最新一期《Cancer Cell》刊发了由北京大学肿瘤医院与该校分子医学研究所、基础医学院的研究人员合作完成的研究文章。该文报导了我国在肝细胞癌干细胞标志物和治疗方面的最新研究成果。北京大学肿瘤医院张志谦 研究员和邢宝才主任医师是该篇文章的共同责任作者，是基础和临床相互合作的一个成功范例。
7 p6 K: Y' |) {9 r5 g
4 ~; z1 {5 D* R. t! w' o, [: v　　我国是肝癌高发的地区，约占世界新发病例的55%，其中80-90%为肝细胞癌。由于大多数肝细胞癌在诊断时即丧失手术机会，且对常规化疗和放疗的反应有限，而那些可手术的病例又面临高达50%的术后两年复发率，因此肝癌死亡率极高。肿瘤干细胞的存在被认为是肿瘤发生、发展和治疗失败的根本原因，因此发现和鉴定肝细胞癌的肿瘤干细胞、研发针对肿瘤干细胞的治疗手段有望为肝癌的治疗带来新的曙光。

goodboy

回复 ag2017 的帖子
  E& t- r/ C- B* \  j4 _( b/ |' ^9 ^1 l: Y
求原文或题目

weijunning

原文哪？
6 t* S1 c& w- N8 p. ~2 _2 n

digsea1984

能不能发原文看看？

biohacker

Cancer Cell, Volume 23, Issue 4, 541-556, 15 April 2013
4 D" {2 L& k. \7 v# y1B50-1, a mAb Raised against Recurrent Tumor Cells, Targets Liver Tumor-Initiating Cells by Binding to the Calcium Channel α2δ1 Subunit$ u6 C  A6 K. R, Y# w
Wei Zhao, Limin Wang, Haibo Han, Kemin Jin, Na Lin, Ting Guo, Yangde Chen, Heping Cheng, Fengmin Lu, Weigang Fang, Yu Wang, Baocai Xing, Zhiqian Zhang( }( l: y: K" `0 Z! ]
The identification and targeted therapy of cells involved in hepatocellular carcinoma (HCC) recurrence remain challenging. Here, we generated a monoclonal antibody against recurrent HCC, 1B50-1, that bound the isoform 5 of the α2δ1 subunit of voltage-gated calcium channels and identified a subset of tumor-initiating cells (TICs) with stem cell-like properties. A surgical margin with cells detected by 1B50-1 predicted rapid recurrence. Furthermore, 1B50-1 had a therapeutic effect on HCC engraftments by eliminating TICs. Finally, α2δ1 knockdown reduced self-renewal and tumor formation capacities and induced apoptosis of TICs, whereas its overexpression led to enhanced sphere formation, which is regulated by calcium influx. Thus, α2δ1 is a functional liver TIC marker, and its inhibitors may serve as potential anti-HCC drugs.  B$ Q, B: U0 P( p1 i4 j: y& U6 C
http://www.sciencedirect.com/science/article/pii/S1535610813000792
7 M% Y* S0 \( Q
9 y- R7 U5 |+ Y' [8 R0 t* v% M% Q这项研究厉害，分子实验、细胞实验、动物实验、临床实验，包全了
2 S! R# K$ z9 E. R$ i% o他们发现的这个靶向肝癌细胞和肝癌干细胞的抗体1B50-1，一定要先保护起来% h# z! I# P2 F% ]$ M
如果开发成肝癌的特异性药物，那就发达了